Company: SMNR
Filing Date: 2025-08-12
Form Type: S-4/A
Source: 0001193125-25-178821
Chunk: 238

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-08-12
Form: S-4/A
Chunk 238
---
nur’s product candidate; |

| • |     | unanticipated serious safety concerns related to the use of any of New Semnur’s product candidate; |

| • |     | adverse regulatory decisions; |

| • |     | changes in laws or regulations applicable to New Semnur’s product candidate, including but not limited to clinical trial requirements for approvals; |

| • |     | legal disputes or other developments relating to proprietary rights, including patents, litigation matters and New Semnur’s ability to obtain patent protection for its product candidate, government investigations and the results of any proceedings or lawsuits, including, but not limited to, patent or stockholder litigation; |

| • |     | New Semnur’s decision to initiate a clinical trial, not initiate a clinical trial or to terminate an existing clinical trial; |

| • |     | New Semnur’s dependence on third parties; |

| • |     | announcements of the introduction of new products by New Semnur’s competitors; |

| • |     | market conditions and trends in the pharmaceutical and biotechnology sectors; |

| • |     | announcements concerning product development results or intellectual property rights of others; |

| • |     | future issuances of common stock or other securities; |

| • |     | the recruitment or departure of key personnel; |

| • |     | failure to meet or exceed any financial guidance or expectations regarding product development milestones that New Semnur may provide to the public; |

| • |     | actual or anticipated variations in quarterly operating results; |

| • |     | New Semnur’s failure to meet or exceed the estimates and projections of the investment community; |

131

| • |     | overall performance of the equity markets and other factors that may be unrelated to New Semnur’s operating performance or the operating performance of its competitors, including changes in market valuations of similar companies; |

| • |     | announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by New Semnur or its competitors; |

| • |     | changes in financial estimates by New Semnur or by any securities analysts who might cover its stock; |

| • |     | fluctuation of the market values of any of New Semnur’s potential strategic investments; |

| • |     | issuances of debt or equity securities; |

| • |     | compliance with New Semnur’s contractual obligations; |

| • |     | sales of New Semnur Common Stock by New Sem